ACADIA announces data from its -015 open label safety study in Parkinson's disease psychosis

7 August 2015

US biotech firm ACADIA Pharmaceuticals (Nasdaq: ACAD) has announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with Nuplazid (pimavanserin) in patients with Parkinson’s disease psychosis (PDP) in the online issue of the Journal of the American Medical Directors Association.

This is the first published report evaluating the long-term impact of antipsychotics on mortality and serious adverse events in patients with PDP.

Currently marketed antipsychotics are not approved for PDP and have a black box warning for use in elderly patients with dementia due to increased mortality and morbidity. Nuplazid was granted Breakthrough Therapy designation from the Food and drug Administration in 2014 and has the potential to be the first drug approved for the treatment of PDP in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK